Fact Check: Does a Johns Hopkins Patent Prove Mebendazole Cures Cancer? No

The claim and the real patent

Posts circulating in late August claimed the 'cancer industry' was hiding a cure because Johns Hopkins researchers held a patent involving mebendazole. The patent is real. It concerns a particular polymorph—a crystal structure—developed to improve how the drug is absorbed and reaches tissue. Confirming that document is the beginning of the check, not proof of the cure claim.

Mebendazole is an antiparasitic medicine used for worm infections. Researchers have studied whether it can be repurposed against cancer, and preclinical work has produced promising signals. A patent can protect a novel composition or use when legal requirements are met; the Patent Office does not run the large controlled human trials needed to establish a therapy's clinical benefit.

What the inventor actually says

Gregory Riggins, the Johns Hopkins professor listed as the first inventor, told AFP that mebendazole's efficacy in oncology has not been established through the necessary larger clinical trials. He said high doses had been found tolerable in cancer patients and could have a reasonable chance of being effective in defined settings, while also acknowledging that the drug may not work.

That position is compatible with continued research and incompatible with the word cure. A candidate can be scientifically plausible, safe enough for further study and still fail to improve survival or quality of life when tested against a control. Cancer is also not one disease, so a result in a brain-cancer model cannot be generalized to every tumor.

The evidence ladder

The social posts collapse those stages into one conclusion. The public record supports research interest and a granted patent. It does not support an accepted, broadly effective human cancer treatment being concealed by the patent's owner.

• Laboratory studies can show effects on cells or biological pathways but cannot reproduce a whole patient's response.
• Animal and model-organism studies can test mechanisms and toxicity while still failing to predict human benefit.
• Early clinical studies focus on dosage and safety and may be too small or uncontrolled to establish effectiveness.
• Larger randomized trials compare outcomes and help distinguish a drug effect from selection, chance and concurrent treatment.

Verdict: False—and potentially dangerous

A Johns Hopkins patent does not prove that mebendazole cures cancer. AFP's expert review found no accepted evidence of a significant benefit in treating human cancers, and the inventor himself emphasized the absence of larger trials. The accurate description is investigational drug-repurposing research.

Patients should not self-medicate or replace oncology care based on viral posts. Riggins warned about drug interactions and the need to monitor liver function and anemia. Anyone interested in a trial can discuss eligibility with an oncology team and verify studies through recognized registries rather than a seller or influencer promising a hidden cure.